Abstract:Objective: The aim at the current study was to investigate the clinical characteristics and risk factors of Raynaud's phenomenon (RP) in patients with primary Sjögren's syndrome (pSS). Methods: Retrospective analysis of the medical records of 333 new-onset pSS patients was performed. Demographic, clinical, and serological data were compared between individuals with and without RP. Logistic regression analysis was used to identify risk factors. Results: RP was present in 11.41% of the pSS patients. pSS-RP patients were younger (49.74±14.56 years vs. 54.46±13.20 years, p=0.04) and exhibited higher disease activity (11 [5.75-15] vs. 7 [4-12], p=0.03) than those without. The prevalence of lung involvement was significantly higher in pSS patients with RP (60.53% vs. 17.29%; p<0.001). A significantly higher proportion of patients with pSS-RP tested positive about antinuclear (ANA), anti-RNP, and anti-centromere antibodies (ACA) compared to those without (p=0.003, <0.001, and 0.01, respectively). Multivariate analysis identified lung involvement (odds ratio [OR]=8.81, 95% confidence interval [CI] 2.02-38.47; p=0.04), anti-RNP positive status (OR=79.41, 95% CI 12.57-501.78; p<0.0001), as well as ACA (OR=13.17, 95% CI 2.60-66.72; p=0.002) as prognostic factors for pSS-RP. Conclusion: The presence of RP defined a subset of pSS with a unique phenotype, manifesting as increased lung involvement and a higher frequency of anti-RNP antibodies and ACA, as well as greater disease activity. These results suggest that RP has clinical and prognostic value of pSS patients. Further prospective studies with a larger number of subjects are warranted to confirm our findings and assess the prognostic and treatment implications of RP in pSS patients. Key Points • Raynaud's phenomenon (RP) was present in 38 (11.41%) of 333 patients with primary Sjögren's syndrome (pSS), with patients with RP exhibiting a younger age and higher disease activity. • The presence of RP indicates a subset of pSS with a unique phenotype, with manifestations including increased lung involvement and a higher frequency of anti-RNP antibodies and anti-centromere antibodies. • Patients with pSS and RP need close follow-up and long-term observation (including assessment of microangiopathy), with specific attention paid to the possible development of clinical features of systemic sclerosis.

Raynaud's phenomenon associated with psoriatic arthritis

The clinical relevance of Raynaud’s phenomenon symptom characteristics in systemic sclerosis

Puffy Fingers and Abnormal Nail Fold Capillaries.

Nail Changes as the Initial Sign of Psoriasis: A Case Report

Nailfold capillary abnormalities are associated with increased severity of Raynaud’s phenomenon among patients with systemic sclerosis: a pilot study

[An atypical presentation of atherosclerosis in psoriasis: "Porcelain aorta"]

Primary Raynaud's Phenomenon of the Tongue

Secukinumab-induced Raynaud’s phenomenon: first report in the literature

Mechanisms of Raynaud's disease

Jaccoud’s Arthropathy and Psoriatic Arthritis, a Rare Association

Nail Changes as the Initial Sign of Psoriasis

Rapidly Progressive Stiffness and Nodularity of Both Hands in a Middle-aged Woman

Cold Hands or Feet: Is It Raynaud's or Not?

Clinical features and risk factors of Raynaud's phenomenon in primary Sjögren's syndrome

Active Pattern on Nailfold Capillaroscopy in a Patient with Systemic Sclerosis.

Pulmonary hypertension secondary to seronegative rheumatoid arthritis overlapping antisynthetase syndrome: A case report

Beyond rheumatoid nodules in rheumatoid arthritis

The impact of season, environmental temperature and humidity on Raynaud phenomenon in an Australian systemic sclerosis cohort

Differentiating Psoriatic Arthritis Sine Psoriasis from Seronegative Rheumatoid Arthritis-Experiences from Five Patients.

Mixed connective tissue disease associated with antineutrophil cytoplasmic antibodies against proteinase-3 and systemic atherosclerosis: a case report

Capillaroscopic differences between primary Raynaud phenomenon and healthy controls indicate potential microangiopathic involvement in benign vasospasms